Literature DB >> 1994286

Disposition of cerebral metastases from malignant melanoma: implications for radiosurgery.

P Davey1, P O'Brien.   

Abstract

Radiosurgery is becoming more generally available and indications for its use continue to be defined. Cerebral metastases from malignant melanoma are often treated with whole-brain irradiation, but with limited benefit. Innovative treatments, such as radiosurgery, make possible the delivery of doses of radiation that are higher than usual. To determine how many patients might be candidates for radiosurgery, a retrospective analysis of computed tomographic brain scans performed on 41 patients with cerebral metastases from malignant melanoma was undertaken. One-third of these patients were found to have cerebral metastases amenable to a radiosurgical approach, as illustrated radiation dose-volume histograms. Patient and tumor characteristics suggest that this series is represent with cerebral metastases from malignant melanoma. The implications of radiosurgery for normal tissue radiation tolerance and its effects on melanoma are discussed.

Entities:  

Mesh:

Year:  1991        PMID: 1994286

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  5 in total

Review 1.  Brain metastases: 1995. A brief review.

Authors:  J B Posner
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

Review 2.  Brain metastases: treatment options to improve outcomes.

Authors:  Phillip Davey
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

3.  Dynamic stereotactic radiosurgery in the palliative treatment of cerebral metastatic tumors.

Authors:  J L Caron; L Souhami; E B Podgorsak
Journal:  J Neurooncol       Date:  1992-02       Impact factor: 4.130

4.  Radiation-induced necrosis deteriorating neurological symptoms and mimicking progression of brain metastasis after stereotactic-guided radiotherapy.

Authors:  Young Zoon Kim; Dae Yong Kim; Heon Yoo; Hee Seok Yang; Sang Hoon Shin; Eun Kyung Hong; Kwan Ho Cho; Seung Hoon Lee
Journal:  Cancer Res Treat       Date:  2007-03-31       Impact factor: 4.679

5.  MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors.

Authors:  Dvora Nass; Shai Rosenwald; Eti Meiri; Shlomit Gilad; Hilla Tabibian-Keissar; Anat Schlosberg; Hagit Kuker; Netta Sion-Vardy; Ana Tobar; Oleg Kharenko; Einat Sitbon; Gila Lithwick Yanai; Eran Elyakim; Hila Cholakh; Hadas Gibori; Yael Spector; Zvi Bentwich; Iris Barshack; Nitzan Rosenfeld
Journal:  Brain Pathol       Date:  2008-07-02       Impact factor: 6.508

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.